English

Supernus Pharmaceuticals, Inc.

EDGAR

SUPN Quarterly report (10-Q) · filed 2026-10-29

Annual consolidated revenue for 2025: about USD 719M, using the latest reported figures. The previous period, 2024, was about USD 661.8M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

227 million USD

2026 Q3 · USD

Exact inputs and evidence

Revenue: 226771000 USD Source

Operating margin

9.34%

2026 Q3 · %

Exact inputs and evidence

Operating Income: 21179000 USD Source
Revenue: 226771000 USD Source

Operating cash flow

6.61 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 68320000 USD Source
Operating Cash Flow: 61714000 USD Source

Free cash flow

6.38 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 68320000 USD Source
Operating Cash Flow: 61714000 USD Source
Capital Expenditure: 798000 USD Source
Capital Expenditure: 568000 USD Source

Cash and cash equivalents: 176 million USD 2026-09-30 Source
Exact value

175884000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 58.3 million shares 2026-09-30 Source
Exact value

58254131 shares

Reported share-count change

1.99% · 1.13 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

57119153 shares · 2025-09-30· Source
58254131 shares · 2026-09-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-29.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+8.6%

Prior period

USD 661.82 million

2024-01-01 – 2024-12-31
Current period

USD 718.95 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

718952000 − 661817000 = 57135000 USD

661817000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
718952000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Year-over-year change in Revenue: 57135000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 718952000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1870674 Filing: 000135657626000011 Input fundies:Revenue: 661817000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1871649 Filing: 000135657626000011
The citation records this snapshot. The page link may show a newer release later.
Net income
-152.2%

Prior period

USD 73.87 million

2024-01-01 – 2024-12-31
Current period

−USD 38.55 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-38550000 − 73865000 = -112415000 USD

73865000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-38550000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Year-over-year change in Net income: -112415000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -38550000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#2270747 Filing: 000135657626000011 Input fundies:NetIncome: 73865000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#2271520 Filing: 000135657626000011
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-72.5%

Prior period

USD 171.95 million

2024-01-01 – 2024-12-31
Current period

USD 47.33 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

47331000 − 171951000 = -124620000 USD

171951000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
47331000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Year-over-year change in Operating cash flow: -124620000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 47331000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1541506 Filing: 000135657626000011 Input fundies:OperatingCashFlow: 171951000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1542153 Filing: 000135657626000011
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+84.6%

Prior period

USD 725,000

2024-01-01 – 2024-12-31
Current period

USD 1.34 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1338000 − 725000 = 613000 USD

725000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1338000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Year-over-year change in Capital expenditure: 613000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1338000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1550831 Filing: 000135657626000011 Input fundies:CapitalExpenditure: 725000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1551421 Filing: 000135657626000011
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 718.95 million 100% of revenue
Cost of revenue USD 74.56 million 10% of revenue
Operating expenses USD 591.8 million 82% of revenue
Other operating costs Derived USD 114.88 million 16% of revenue
Operating income −USD 62.28 million −8.7% of revenue
Tax, interest and other Derived −USD 23.73 million −3.3% of revenue
Net income −USD 38.55 million −5.4% of revenue

Cash

Operating cash flow USD 47.33 million 6.6% of revenue
Capital expenditure USD 1.34 million 0.2% of revenue
Free cash flow Derived USD 45.99 million 6.4% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 19%14%67%
2018 27%65%
2019 29%9%62%
2020 24%67%
2021 9.2%85%
2022 Net income was higher than operating income, so the split is not drawn.
2023 Operating loss: operating costs were 101% of revenue.
2024 11%88%
2025 Operating loss: operating costs were 109% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	302238000	202697000 Derived	99541000	42257000 Derived	57284000	112611000 Derived	Source 2017-01-01 – 2017-12-31: 302238000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 99541000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 57284000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 114640000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2029000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	408897000	264453000 Derived	144444000	33451000 Derived	110993000	128142000 Derived	Source 2018-01-01 – 2018-12-31: 408897000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 144444000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 110993000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 128986000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 844000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	392755000	244184000 Derived	148571000	35515000 Derived	113056000	140393000 Derived	Source 2019-01-01 – 2019-12-31: 392755000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 148571000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 113056000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 143129000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2736000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	520397000	346699000 Derived	173698000	46748000 Derived	126950000	134950000 Derived	Source 2020-01-01 – 2020-12-31: 520397000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 173698000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 126950000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 138399000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3449000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	579775000	493746000 Derived	86029000	32605000 Derived	53424000	Unavailable	Source 2021-01-01 – 2021-12-31: 579775000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 86029000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 53424000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 127127000 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	667238000	621114000 Derived	46124000	-14587000 Derived	60711000	116414000 Derived	Source 2022-01-01 – 2022-12-31: 667238000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 46124000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 60711000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 116826000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 412000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	607521000	612790000 Derived	-5269000	-6585000 Derived	1316000	110534000 Derived	Source 2023-01-01 – 2023-12-31: 607521000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -5269000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 1316000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 111085000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 551000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	661817000	580151000 Derived	81666000	7801000 Derived	73865000	171226000 Derived	Source 2024-01-01 – 2024-12-31: 661817000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: 81666000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 73865000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 171951000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 725000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	718952000	781235000 Derived	-62283000	-23733000 Derived	-38550000	45993000 Derived	Source 2025-01-01 – 2025-12-31: 718952000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -62283000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -38550000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 47331000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1338000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 719M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	302238000	Revenue: 302238000 Open source
20182018-12-31	Revenue	408897000	Revenue: 408897000 Open source
20192019-12-31	Revenue	392755000	Revenue: 392755000 Open source
20202020-12-31	Revenue	520397000	Revenue: 520397000 Open source
20212021-12-31	Revenue	579775000	Revenue: 579775000 Open source
20222022-12-31	Revenue	667238000	Revenue: 667238000 Open source
20232023-12-31	Revenue	607521000	Revenue: 607521000 Open source
20242024-12-31	Revenue	661817000	Revenue: 661817000 Open source
20252025-12-31	Revenue	718952000	Revenue: 718952000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

8.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 302238000 Open source
20182018-12-31	Year over year	35.3%	Revenue: 408897000 Open source Revenue: 302238000 Open source
20192019-12-31	Year over year	-3.9%	Revenue: 392755000 Open source Revenue: 408897000 Open source
20202020-12-31	Year over year	32.5%	Revenue: 520397000 Open source Revenue: 392755000 Open source
20212021-12-31	Year over year	11.4%	Revenue: 579775000 Open source Revenue: 520397000 Open source
20222022-12-31	Year over year	15.1%	Revenue: 667238000 Open source Revenue: 579775000 Open source
20232023-12-31	Year over year	-8.9%	Revenue: 607521000 Open source Revenue: 667238000 Open source
20242024-12-31	Year over year	8.9%	Revenue: 661817000 Open source Revenue: 607521000 Open source
20252025-12-31	Year over year	8.6%	Revenue: 718952000 Open source Revenue: 661817000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -8.7% 2025

Net margin -5.4% 2025

Free cash flow margin 6.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	32.9%	Operating Income: 99541000 Open source Revenue: 302238000 Open source
20182018-12-31	Operating margin	35.3%	Operating Income: 144444000 Open source Revenue: 408897000 Open source
20192019-12-31	Operating margin	37.8%	Operating Income: 148571000 Open source Revenue: 392755000 Open source
20202020-12-31	Operating margin	33.4%	Operating Income: 173698000 Open source Revenue: 520397000 Open source
20212021-12-31	Operating margin	14.8%	Operating Income: 86029000 Open source Revenue: 579775000 Open source
20222022-12-31	Operating margin	6.9%	Operating Income: 46124000 Open source Revenue: 667238000 Open source
20232023-12-31	Operating margin	-0.9%	Operating Income: -5269000 Open source Revenue: 607521000 Open source
20242024-12-31	Operating margin	12.3%	Operating Income: 81666000 Open source Revenue: 661817000 Open source
20252025-12-31	Operating margin	-8.7%	Operating Income: -62283000 Open source Revenue: 718952000 Open source
20172017-12-31	Net margin	19%	Net Income: 57284000 Open source Revenue: 302238000 Open source
20182018-12-31	Net margin	27.1%	Net Income: 110993000 Open source Revenue: 408897000 Open source
20192019-12-31	Net margin	28.8%	Net Income: 113056000 Open source Revenue: 392755000 Open source
20202020-12-31	Net margin	24.4%	Net Income: 126950000 Open source Revenue: 520397000 Open source
20212021-12-31	Net margin	9.2%	Net Income: 53424000 Open source Revenue: 579775000 Open source
20222022-12-31	Net margin	9.1%	Net Income: 60711000 Open source Revenue: 667238000 Open source
20232023-12-31	Net margin	0.2%	Net Income: 1316000 Open source Revenue: 607521000 Open source
20242024-12-31	Net margin	11.2%	Net Income: 73865000 Open source Revenue: 661817000 Open source
20252025-12-31	Net margin	-5.4%	Net Income: -38550000 Open source Revenue: 718952000 Open source
20172017-12-31	Free cash flow margin	37.3%	Revenue: 302238000 Open source Operating Cash Flow: 114640000 Open source Capital Expenditure: 2029000 Open source
20182018-12-31	Free cash flow margin	31.3%	Revenue: 408897000 Open source Operating Cash Flow: 128986000 Open source Capital Expenditure: 844000 Open source
20192019-12-31	Free cash flow margin	35.7%	Revenue: 392755000 Open source Operating Cash Flow: 143129000 Open source Capital Expenditure: 2736000 Open source
20202020-12-31	Free cash flow margin	25.9%	Revenue: 520397000 Open source Operating Cash Flow: 138399000 Open source Capital Expenditure: 3449000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 579775000 Open source Operating Cash Flow: 127127000 Open source
20222022-12-31	Free cash flow margin	17.4%	Revenue: 667238000 Open source Operating Cash Flow: 116826000 Open source Capital Expenditure: 412000 Open source
20232023-12-31	Free cash flow margin	18.2%	Revenue: 607521000 Open source Operating Cash Flow: 111085000 Open source Capital Expenditure: 551000 Open source
20242024-12-31	Free cash flow margin	25.9%	Revenue: 661817000 Open source Operating Cash Flow: 171951000 Open source Capital Expenditure: 725000 Open source
20252025-12-31	Free cash flow margin	6.4%	Revenue: 718952000 Open source Operating Cash Flow: 47331000 Open source Capital Expenditure: 1338000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 47.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	114640000	Operating Cash Flow: 114640000 Open source
20182018-12-31	Operating cash flow	128986000	Operating Cash Flow: 128986000 Open source
20192019-12-31	Operating cash flow	143129000	Operating Cash Flow: 143129000 Open source
20202020-12-31	Operating cash flow	138399000	Operating Cash Flow: 138399000 Open source
20212021-12-31	Operating cash flow	127127000	Operating Cash Flow: 127127000 Open source
20222022-12-31	Operating cash flow	116826000	Operating Cash Flow: 116826000 Open source
20232023-12-31	Operating cash flow	111085000	Operating Cash Flow: 111085000 Open source
20242024-12-31	Operating cash flow	171951000	Operating Cash Flow: 171951000 Open source
20252025-12-31	Operating cash flow	47331000	Operating Cash Flow: 47331000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 46M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	112611000	Operating Cash Flow: 114640000 Open source Capital Expenditure: 2029000 Open source
20182018-12-31	Free cash flow	128142000	Operating Cash Flow: 128986000 Open source Capital Expenditure: 844000 Open source
20192019-12-31	Free cash flow	140393000	Operating Cash Flow: 143129000 Open source Capital Expenditure: 2736000 Open source
20202020-12-31	Free cash flow	134950000	Operating Cash Flow: 138399000 Open source Capital Expenditure: 3449000 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: 127127000 Open source
20222022-12-31	Free cash flow	116414000	Operating Cash Flow: 116826000 Open source Capital Expenditure: 412000 Open source
20232023-12-31	Free cash flow	110534000	Operating Cash Flow: 111085000 Open source Capital Expenditure: 551000 Open source
20242024-12-31	Free cash flow	171226000	Operating Cash Flow: 171951000 Open source Capital Expenditure: 725000 Open source
20252025-12-31	Free cash flow	45993000	Operating Cash Flow: 47331000 Open source Capital Expenditure: 1338000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

26.9% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Liabilities / assets	Not reported	No source recorded
20182018-12-31	Liabilities / assets	53.7%	Total Liabilities: 524788000 Open source Total Assets: 977811000 Open source
20192019-12-31	Liabilities / assets	48.7%	Total Liabilities: 564854000 Open source Total Assets: 1160282000 Open source
20202020-12-31	Liabilities / assets	50.5%	Total Liabilities: 759244000 Open source Total Assets: 1504102000 Open source
20212021-12-31	Liabilities / assets	51.7%	Total Liabilities: 873301000 Open source Total Assets: 1689152000 Open source
20222022-12-31	Liabilities / assets	47.9%	Total Liabilities: 816304000 Open source Total Assets: 1702508000 Open source
20232023-12-31	Liabilities / assets	27.9%	Total Liabilities: 356157000 Open source Total Assets: 1277673000 Open source
20242024-12-31	Liabilities / assets	24.3%	Total Liabilities: 332340000 Open source Total Assets: 1368073000 Open source
20252025-12-31	Liabilities / assets	26.9%	Total Liabilities: 390934000 Open source Total Assets: 1452648000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.9× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Current assets / current liabilities	Not reported	No source recorded
20182018-12-31	Current assets / current liabilities	3.06×	Current Assets: 493487000 Open source Current Liabilities: 161353000 Open source
20192019-12-31	Current assets / current liabilities	2.94×	Current Assets: 472644000 Open source Current Liabilities: 160587000 Open source
20202020-12-31	Current assets / current liabilities	2.57×	Current Assets: 630417000 Open source Current Liabilities: 245108000 Open source
20212021-12-31	Current assets / current liabilities	1.91×	Current Assets: 601590000 Open source Current Liabilities: 315379000 Open source
20222022-12-31	Current assets / current liabilities	1.07×	Current Assets: 734151000 Open source Current Liabilities: 687958000 Open source
20232023-12-31	Current assets / current liabilities	1.7×	Current Assets: 493113000 Open source Current Liabilities: 290196000 Open source
20242024-12-31	Current assets / current liabilities	2.35×	Current Assets: 686070000 Open source Current Liabilities: 292397000 Open source
20252025-12-31	Current assets / current liabilities	1.9×	Current Assets: 644182000 Open source Current Liabilities: 338171000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	USD 57.28 million Exact value Exact value: 57284000 USD 2017-01-01 – 2017-12-31: 57284000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2017-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 57284000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 57284000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657620000010/supn-20191231x10k.htm#1551017 Filing: 000135657620000010 The citation records this snapshot. The page link may show a newer release later.	USD 114.64 million Exact value Exact value: 114640000 USD 2017-01-01 – 2017-12-31: 114640000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2017-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 114640000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 114640000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657620000010/supn-20191231x10k.htm#1611907 Filing: 000135657620000010 The citation records this snapshot. The page link may show a newer release later.	USD 2.03 million Exact value Exact value: 2029000 USD 2017-01-01 – 2017-12-31: 2029000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2017-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 2029000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2029000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657620000010/supn-20191231x10k.htm#1623266 Filing: 000135657620000010 The citation records this snapshot. The page link may show a newer release later.	USD 112.61 million Calculation and evidence 114640000 − 2029000 USD Exact free cash flow: 112611000 USD 2017-01-01 – 2017-12-31: 114640000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2029000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2017-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 112611000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 114640000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657620000010/supn-20191231x10k.htm#1611907 Filing: 000135657620000010 Input fundies:CapitalExpenditure: 2029000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657620000010/supn-20191231x10k.htm#1623266 Filing: 000135657620000010 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 110.99 million Exact value Exact value: 110993000 USD 2018-01-01 – 2018-12-31: 110993000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2018-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 110993000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 110993000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1509019 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.	USD 128.99 million Exact value Exact value: 128986000 USD 2018-01-01 – 2018-12-31: 128986000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2018-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 128986000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 128986000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1554673 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.	USD 844,000 Exact value Exact value: 844000 USD 2018-01-01 – 2018-12-31: 844000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2018-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 844000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 844000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1571772 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.	USD 128.14 million Calculation and evidence 128986000 − 844000 USD Exact free cash flow: 128142000 USD 2018-01-01 – 2018-12-31: 128986000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 844000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2018-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 128142000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 128986000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1554673 Filing: 000135657621000028 Input fundies:CapitalExpenditure: 844000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1571772 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 113.06 million Exact value Exact value: 113056000 USD 2019-01-01 – 2019-12-31: 113056000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2019-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 113056000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 113056000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657622000025/supn-20211231.htm#1515710 Filing: 000135657622000025 The citation records this snapshot. The page link may show a newer release later.	USD 143.13 million Exact value Exact value: 143129000 USD 2019-01-01 – 2019-12-31: 143129000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2019-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 143129000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 143129000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657622000025/supn-20211231.htm#1564454 Filing: 000135657622000025 The citation records this snapshot. The page link may show a newer release later.	USD 2.74 million Exact value Exact value: 2736000 USD 2019-01-01 – 2019-12-31: 2736000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2019-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 2736000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2736000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1570791 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.	USD 140.39 million Calculation and evidence 143129000 − 2736000 USD Exact free cash flow: 140393000 USD 2019-01-01 – 2019-12-31: 143129000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2736000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2019-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 140393000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 143129000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657622000025/supn-20211231.htm#1564454 Filing: 000135657622000025 Input fundies:CapitalExpenditure: 2736000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1570791 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 126.95 million Exact value Exact value: 126950000 USD 2020-01-01 – 2020-12-31: 126950000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2020-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 126950000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 126950000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000016/supn-20221231.htm#2528457 Filing: 000135657623000016 The citation records this snapshot. The page link may show a newer release later.	USD 138.4 million Exact value Exact value: 138399000 USD 2020-01-01 – 2020-12-31: 138399000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2020-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 138399000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 138399000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000016/supn-20221231.htm#1605433 Filing: 000135657623000016 The citation records this snapshot. The page link may show a newer release later.	USD 3.45 million Exact value Exact value: 3449000 USD 2020-01-01 – 2020-12-31: 3449000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2020-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 3449000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3449000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1569810 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.	USD 134.95 million Calculation and evidence 138399000 − 3449000 USD Exact free cash flow: 134950000 USD 2020-01-01 – 2020-12-31: 138399000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3449000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2020-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 134950000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 138399000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000016/supn-20221231.htm#1605433 Filing: 000135657623000016 Input fundies:CapitalExpenditure: 3449000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657621000028/supn-20201231.htm#1569810 Filing: 000135657621000028 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 53.42 million Exact value Exact value: 53424000 USD 2021-01-01 – 2021-12-31: 53424000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2021-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 53424000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 53424000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000013/supn-20231231.htm#2067390 Filing: 000135657624000013 The citation records this snapshot. The page link may show a newer release later.	USD 127.13 million Exact value Exact value: 127127000 USD 2021-01-01 – 2021-12-31: 127127000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2021-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 127127000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 127127000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000013/supn-20231231.htm#1467029 Filing: 000135657624000013 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	USD 60.71 million Exact value Exact value: 60711000 USD 2022-01-01 – 2022-12-31: 60711000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2022-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 60711000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 60711000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000017/supn-20241231.htm#2003043 Filing: 000135657625000017 The citation records this snapshot. The page link may show a newer release later.	USD 116.83 million Exact value Exact value: 116826000 USD 2022-01-01 – 2022-12-31: 116826000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2022-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 116826000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 116826000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000017/supn-20241231.htm#1429636 Filing: 000135657625000017 The citation records this snapshot. The page link may show a newer release later.	USD 412,000 Exact value Exact value: 412000 USD 2022-01-01 – 2022-12-31: 412000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2022-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 412000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 412000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000017/supn-20241231.htm#1436896 Filing: 000135657625000017 The citation records this snapshot. The page link may show a newer release later.	USD 116.41 million Calculation and evidence 116826000 − 412000 USD Exact free cash flow: 116414000 USD 2022-01-01 – 2022-12-31: 116826000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 412000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2022-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 116414000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 116826000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000017/supn-20241231.htm#1429636 Filing: 000135657625000017 Input fundies:CapitalExpenditure: 412000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000017/supn-20241231.htm#1436896 Filing: 000135657625000017 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	USD 1.32 million Exact value Exact value: 1316000 USD 2023-01-01 – 2023-12-31: 1316000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2023-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 1316000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1316000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#2272290 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 111.09 million Exact value Exact value: 111085000 USD 2023-01-01 – 2023-12-31: 111085000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2023-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 111085000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 111085000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1542802 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 551,000 Exact value Exact value: 551000 USD 2023-01-01 – 2023-12-31: 551000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2023-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 551000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 551000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1551981 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 110.53 million Calculation and evidence 111085000 − 551000 USD Exact free cash flow: 110534000 USD 2023-01-01 – 2023-12-31: 111085000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 551000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2023-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 110534000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 111085000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1542802 Filing: 000135657626000011 Input fundies:CapitalExpenditure: 551000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1551981 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	USD 73.87 million Exact value Exact value: 73865000 USD 2024-01-01 – 2024-12-31: 73865000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2024-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: 73865000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: 73865000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#2271520 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 171.95 million Exact value Exact value: 171951000 USD 2024-01-01 – 2024-12-31: 171951000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2024-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 171951000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 171951000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1542153 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 725,000 Exact value Exact value: 725000 USD 2024-01-01 – 2024-12-31: 725000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2024-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 725000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 725000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1551421 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 171.23 million Calculation and evidence 171951000 − 725000 USD Exact free cash flow: 171226000 USD 2024-01-01 – 2024-12-31: 171951000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 725000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2024-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 171226000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 171951000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1542153 Filing: 000135657626000011 Input fundies:CapitalExpenditure: 725000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1551421 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 38.55 million Exact value Exact value: -38550000 USD 2025-01-01 – 2025-12-31: -38550000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Net Income: -38550000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38550000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#2270747 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 47.33 million Exact value Exact value: 47331000 USD 2025-01-01 – 2025-12-31: 47331000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Operating Cash Flow: 47331000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 47331000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1541506 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 1.34 million Exact value Exact value: 1338000 USD 2025-01-01 – 2025-12-31: 1338000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Capital Expenditure: 1338000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1338000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1550831 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.	USD 45.99 million Calculation and evidence 47331000 − 1338000 USD Exact free cash flow: 45993000 USD 2025-01-01 – 2025-12-31: 47331000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1338000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Supernus Pharmaceuticals, Inc. · 2025-12-31 Supernus Pharmaceuticals, Inc. (edgar:1356576) Free cash flow: 45993000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:09:05Z Snapshot: 35dd277a1473d78cfabb2e86470d3cb8594a104f66b7d32ec5ddad0295ce8b2b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1356576?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 47331000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1541506 Filing: 000135657626000011 Input fundies:CapitalExpenditure: 1338000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm#1550831 Filing: 000135657626000011 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

83 filings · 5,955 latest values · 5,955 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001356576, 1356576, SUPN, edgar:1356576

Also known as SUPERNUS PHARMACEUTICALS INC, SUPERNUS PHARMACEUTICALS, INC., SUPERNUS PHARMACEUTICALS, INC., Supernus Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation